Medtronic PLC (N:MDT)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 20 On Hatch, Hatch Street Lower
Tel: 1-763-5052692
IR: See website
Key People
Omar Syed Ishrak
Chairman of the Board, Chief Executive Officer
Bradley E. Lerman
Senior Vice President, General Counsel, Corporate secretary
Karen L. Parkhill
Chief Financial Officer, Executive Vice President
Carol A. Surface
Chief Human Resource Officer, Senior Vice President
Michael J. Coyle
Executive Vice President, Group President - Cardiac and Vascular Group
Hooman C. Hakami
Executive Vice President and Group President of the Diabetes Group
Robert ten Hoedt
Executive Vice President and President - EMEAC
Geoffrey S. Martha
Executive Vice President and President - Restorative Therapies Group
Robert J. White
Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group
Richard E. Kuntz
Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
Business Overview
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Financial Overview
For the nine months ended 25 January 2019, Medtronic PLC revenues increased 3% to $22.41B. Net income before extraordinary items decreased 12% to $3.43B. Revenues reflect Restrrative Therapies Group segment increase of 6% to $5.97B, Diabetes segment increase of 18% to $1.77B, Rest of World segment increase from $3.44B to $10.43B, United States segment increase of 3% to $11.91B.
Employees: 86,000 as of Apr 27, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $138,898M as of Jan 25, 2019
Annual revenue (TTM): $30,555M as of Jan 25, 2019
EBITDA (TTM): $9,190M as of Jan 25, 2019
Net annual income (TTM): $5,105M as of Jan 25, 2019
Free cash flow (TTM): $2,221M as of Jan 25, 2019
Net Debt Last Fiscal Year: $15,888M as of Jan 25, 2019
Shares outstanding: 1,341,150,970 as of Feb 27, 2019
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization